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Abstract: A new type of metabolizable and efficient radiosensitizer for cancer radiotherapy is 
presented in this study by combining ultrasmall Au nanoclusters (NCs, <2 nm) with 
biocompatible coating ligands (glutathione, GSH). The new nano-construct (GSH-coated 
Au25 NCs) inherits attractive features of both the Au core (strong radiosensitizing effect) and 
GSH shell (good biocompatibility). It can preferentially accumulate in tumor via the improved 
EPR effect, which leads to strong enhancement for cancer radiotherapy. After the treatment, 
the small-sized GSH-Au25 NCs can be efficiently cleared by the kidney, minimizing any 
potential side effects due to the accumulation of Au25 NCs in the body. 
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1. Introduction 
 
Gold nanoparticles (Au NPs) possess distinct physical and chemical properties that make 
them ideal platforms for a variety of biomedical applications, including imaging, biosensing, 
drug delivery, and therapy.[1] Recently, Au NPs have been applied as a promising new type of 
radiotherapy sensitizing agents (or radiosensitizers) for cancer treatment because of their 
strong absorption and high efficiency in generating secondary electrons under gamma ray or 
X-ray irradiation, enhancing the DNA and protein damages in tumors.[2] A good 
radiosensitizer must feature two properties: (1) efficient accumulation in tumors during the 
radiation treatment to achieve sufficient enhancement for the radiotherapy, and (2) effective 
renal clearance after the treatment to minimize toxic side effects. Here we report a novel type 
of Au NP-based radiosensitizers: ultrasmall Au NPs (<2 nm) protected by naturally occurring 
biomolecules (e.g., peptides and proteins). The complementary features of the two key 
components, the sub-2 nm Au core and the biomolecule coating, are integrated into a single 
entity, that is, biomolecule-coated ultrasmall Au NPs, to achieve targeted properties of a good 
radiosensitizer. 
 
Ultrasmall Au NPs were chosen in this study as the radiosensitizer. Sub-2 nm Au NPs, or 
termed Au nanoclusters (NCs), are a subgenre of NPs with a core size below 2 nm typically 
containing less than 150 Au atoms.[3] Recent studies have shown that the accumulation 
efficiency of Au NPs in tumors was largely determined by the particle size, and smaller Au 
NPs have higher efficient tumor deposition. For example, it is well-documented that Au NPs 
with sizes >50 nm cannot pass through the outside barrier of the reticuloendothelial system 
(RES) but to form large aggregates (>100 nm) during the blood circulation, which led to a 
poor deposition of NPs in tumors.[4] In contrast, Au NPs with sizes <50 nm showed radiation 
enhancement effects to a certain extent, suggesting the accumulation of the NPs in tumors.[2a, 
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5] In addition, 12 nm Au NPs coated with polyethylene glycol (PEG) showed obviously higher 
accumulation in tumors than those of 27.6 and 46.6 nm PEG-coated Au NPs.[2b, 6] It is 
therefore expected that the ultrasmall Au NCs (< 2 nm) may have improved accumulation in 
tumors because of their enhanced permeability and retention (EPR) effect relative to that of 
large NPs (>2 nm),[7] leading to an improved enhancement for cancer radiotherapy. 
 
Coating ligands on the NP surface can also affect the pharmacokinetics of Au NPs in the body 
by controlling the surface chemistry and hydrodynamic diameter (HD) of the Au NPs, which 
are two primary factors that can affect the properties and behavior of Au NPs under 
physiological conditions.[8] For example, 3 nm Au NPs coated with different ligands showed 
different colloidal stability in the body: the PEG-coated Au NPs were not stable and formed 
aggregates in blood, whereas the glutathione (GSH)-coated Au NPs were highly stable under 
the same conditions.[9] The different behaviors of Au NPs in blood may lead to different 
deposition efficiencies in tumors. Due to the ultrasmall size of Au NCs, the effect of coating 
ligands on their pharmacokinetics in the body could be more pronounced than that of larger 
NPs.[10] In addition, the biocompatibility of the coating ligands on the NP surface is a key 
consideration for all biomedical applications, and a good compliance strategy is to select a 
naturally occurring biomolecule as the coating ligand.[11] The natural peptide – GSH and the 
bovine serum albumin (BSA) are widely used as biocompatible coating ligands for Au NPs in 
various biomedical settings. Therefore, we hypothesized that an efficient and safe 
radiosensitizer could be constructed by incorporating biocompatible ligands (GSH or BSA) 
into the ultrasmall Au NCs, forming GSH- or BSA-coated Au NCs, which may have 
improved passive tumor targeting performance via the EPR effect.  
 
One concern related to the therapeutic Au NPs is biosafety. Au NPs are generally considered 
as safe materials in view of their good biocompatibility and low in vitro cytotoxicity. 
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However, Au NPs with a relatively large size (>10 nm) cannot be metabolized and tend to be 
absorbed by RES and accumulate in liver and spleen, which leads to potential damages to the 
liver and immune system.[12] Recent studies suggested that the HD of the NPs could determine 
the renal clearance efficiency.[9a] For example, semiconductor quantum dots (QDs) with a HD 
<5.5 nm was rapidly and efficiently removed by the kidney, whereas QDs with a HD >15 nm 
did not show efficient renal excretion and were accumulated in the liver and spleen.[13] 
Similarly, the GSH-coated Au NPs with particle size in the range of 1.5–3 nm showed high 
efficiency in the renal clearance.[9-10] 
 
This article is an account of our investigation of the GSH- and BSA-coated Au NCs for 
cancer radiotherapy. The well-studied Au25 NCs species was chosen as the model of the new 
NC-based radiosensitizers because of their ultrasmall size (<2 nm) and excellent chemical 
stability. In vitro and in vivo studies of the GSH- and BSA-coated Au25 NCs (or GSH- and 
BSA-Au25 NCs for short) for cancer radiotherapy are presented here with detailed analyses of 
the cell response, DNA damage, and changes in tumor volume and weight after the treatment. 
In vivo cytotoxicity of GSH-Au25 NCs was investigated with experimental evidences from the 
pathology, biochemistry, organ index, and biodistribution studies. Our findings suggest that 
GSH-Au25 NCs are promising radiosensitizers for cancer radiotherapy with attractive features 
including excellent tumor accumulation, strong radiation enhancement, and low toxicity 
(efficient renal clearance). 
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2. Results and Discussion 
GSH- and BSA-Au25 NCs were synthesized and purified according to published 
procedures.[14] Both types of the NCs have a core-shell structure, as illustrated in Figure 1a 
and 1b. GSH-Au25 NCs, which can be denoted as Au25(SG)18, have molecular-like 
absorptions due to the strong quantum confinement of free electrons in the ultrasmall 
particles.[15] As shown in Figure 1c (black line), the GSH-Au25 NCs showed the UV-vis 
absorption spectrum with a maximum at 670 nm and a few shoulder peaks that matched well 
with earlier studies.[3d, 16] The well-defined absorption spectrum suggested the high purity of 
our sample. The ultrasmall size of GSH-Au25 NCs was demonstrated by the transmission 
electron microscopy (TEM) image (Figure 1e), in which only particles smaller than 1.5 nm 
were observed. BSA-Au25 NC consists of 25 Au atoms encapsulated by a BSA molecule 
(Figure 1b). Unlike GSH-Au25 NCs, BSA-Au25 NCs showed no obvious peaks in its UV-vis 
absorption spectrum (Figure 1c, red line). The distinctive difference in the absorptions of 
GSH- and BSA-Au25 NCs is a result of the strong effects from the different coating ligands 
and protection chemistries, which are more pronounced in the ultrasmall NCs than in large 
NPs. [14a, 17] As suggested by the TEM image (Figure 1f), the core size of BSA-Au25 NCs was 
also below 1.5 nm, similar to that of GSH-Au25 NCs. However, GSH- and BSA-Au25 NCs 
showed very different HDs in dynamic light scattering (DLS) measurements. The HD of 
GSH-Au25 NCs was ~2.4 nm (Figure 1d, black line), which was determined by the small size 
of the GSH ligand [molecular weight (MW) = 307]. In contrast, the BSA-Au25 NCs had a HD 
of ~6 nm, which matched nicely with the size of BSA (MW ~66 kDa and HD ~6 nm) because 
the Au atoms were encapsulated by a single BSA molecule for each BSA-Au25 NC. 
 
The cell responses (or biocompatibility) of GSH- and BSA-Au25 NCs were evaluated using 
the Hela cells. The Hela cell culture was first treated with GSH- or BSA-Au25 NCs at 
different concentrations of 0.00625–0.2 mg-Au/mL. As shown in Figure 2a, after 24 and 48 h, 
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the viability of the cells changed very little with increasing NC concentration. The results 
showed that both GSH- and BSA-Au25 NCs had low cytotoxicity even at a high dosage of 0.2 
mg-Au/mL (after 48 h, the cell viability was ~85% and ~70% for GSH- and BSA-Au25 NCs, 
respectively). The data also suggested that GSH-Au25 NCs had better biocompatibility than 
that of BSA-Au25 NCs. The good biocompatibility of GSH- and BSA-Au25 NCs is expected 
because both GSH and BSA are naturally occurring benign biomolecules.  
 
The radiation enhancements of GSH- and BSA-Au25 NCs were measured by the colony 
formation assay using the Hela cells. As shown in Figure 2b, an obvious enhancement in 
radiation was observed for cell cultures treated with the GSH- or BSA-Au25 NCs. In 
particular, the sensitization enhancement ratio (SER) of GSH-Au25 NCs was ~1.30, which 
was higher than that of BSA-Au25 NCs (~1.21) for all the radiation doses. The radiation 
enhancement effects of GSH- and BSA-Au25 NCs may be due to the enhanced DNA damage 
induced by the photoelectric effect and Compton scattering of the heavy metal, that is, Au. 
This hypothesis was supported by the single-cell gel electrophoresis study. As shown in 
Figure 2c, without radiation, negligible DNA damage was observed for the cell cultures 
treated with GSH- and BSA-Au25 NCs. This data provided yet another line of evidence for 
low cytotoxicity of both GSH- and BSA-Au25 NCs. In contrast, after receiving a 3 Gy 
radiation dose, a significant DNA damage was observed for cell cultures treated with GSH- 
and BSA-Au25 NCs (Figure 2c). The remarkable DNA damage was also suggested by the in 
vitro imaging with fluorescent DNA stain, in which a long tail indicated significant DNA 
damage. There was no obvious DNA damage observed in the control and NCs without 
radiation groups (Figure S1). As compared with the cell culture treated by radiation only 
(Figure 2d), cell cultures treated with GSH- or BSA-Au25 NCs plus radiation (3 Gy) showed 
more significant DNA damages (Figure 2e and 2f). In addition, GSH-Au25 NCs showed 
stronger radiation enhancement than BSA-Au25 NCs, which could be attributed to the 
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improved cell uptake of the hydrodynamically smaller GSH-Au25 NCs (HD ~2.4 nm) relative 
to that of the BSA-Au25 NCs (HD ~6 nm). The different surface chemistry of the coating 
ligands (GSH and BSA) on the NCs might also contribute to the difference in their cell uptake. 
GSH is a ziwitterionic ligand with two carboxyl and one amine groups, which might enhance 
the uptake of the GSH-Au25 NCs by the cells. 
 
In vivo experiments were carried out to further confirm the strong radiation enhancement 
caused by GSH- or BSA-Au25 NCs. We first labeled GSH- and BSA-Au25 NCs with an 
organic dye, Cy5, whose excitation and emission wavelengths were 595 and 680 nm, 
respectively. The Cy5-labeled GSH- and BSA-Au25 NCs also showed red emission peaks at 
around 680 nm when excited at 595 nm (Figure S2). The in vivo pharmacokinetics of GSH- 
and BSA-Au25 NCs in blood were evaluated using male nude mice bearing the U14 tumor 
with a tumor weight of ~10 mg-tumor/kg-body. The mice were intraperitoneally injected with 
Cy5-labeled GSH- or BSA-Au25 NCs (10 mg-Au/kg-body), and the concentrations of GSH- 
or BSA-Au25 NCs in blood were monitored by their fluorescence over a 24 h period after 
injection. As shown in Figure 3a, the half-life of GSH- and BSA-Au25 NCs in blood was 
determined to be ~0.25 and 0.75 h, respectively. As compared with the BSA-Au25 NCs, the 
shorter half-life of GSH-Au25 NCs in blood could be attributed to its much smaller HD. The 
concentrations of both GSH- and BSA-Au25 NCs in blood were gradually stabilized after ~2.5 
h (Figure 3a). The pharmacokinetics of such passive targeting NCs may follow a two-
compartment model in which the biocompatible ligands on the NC surface help the NCs in 
blood penetrate tissues through the transendothelial pores in tumor blood vessels and 
subsequently deposit in the tumor interstitium.[18] 
 
The accumulations of GSH- and BSA-Au25 NCs in tumors were further confirmed by the in 
vivo fluorescence imaging (Figure 3b). Strong fluorescence was observed in the tumor site 
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(indicated by the circle) at 24 h after the injection of Cy5-labeled GSH- or BSA-Au25 NCs. 
Strong fluorescence was also observed in the liver and bladder. The in vivo biodistributions of 
the injected GSH- and BSA-Au25 NCs were evaluated using the fluorescence intensity of the 
tissues at 680 nm when excited by a 595-nm laser. Figure 3c shows that the NCs were rarely 
found in most of the organs except liver and bladder, indicating that the NCs had sufficient 
transit time in the systemic circulation for the deposition in tumor. The depositions of GSH- 
and BSA-Au25 NCs in tumors were ~13.1% and 8.6% ID/g (refers to percentage of the 
injected dose per gram-tissue), respectively. The in vivo biodistribution data of the NCs at day 
20 after injection (Figure S3) was also investigated by measuring the concentrations of Au in 
the dissected organs of sacrificed mice bearing the U14 tumors using inductively coupled 
plasma mass spectrometry (ICP-MS). The Au concentrations in the tumors were ~1456 and 
216 ng/g-tumor in mice treated with GSH- and BSA-Au25 NCs, respectively. These values 
were consistent with the biodistribution data determined from the fluorescence intensity 
(Figure 3b). It is worth mentioning that the Au NCs used in this study showed improved 
tumor accumulation relative to that of larger Au NPs.[19] For example, 6.63% ID/g deposition 
in tumor was observed for 20 nm PEG-Au NPs, but <1% ID/g in tumor was observed for 80 
nm PEG-Au NPs.[4b] These values were much lower than those of our Au NC systems: 13.1% 
and 8.6% ID/g in tumors for GSH- and BSA-Au25 NCs, respectively. In addition, the Au 
concentration in the tumors of mice treated with GSH-Au25 NCs (~1456 ng/g-tumor) was 
much higher than those reported for Au NP-based systems (e.g., 100–300 ng/g-tumor for 5–
50 nm PEG-Au NPs and 100–600 ng/g-tumor for 2–15 nm tiopronin-Au NPs).[2b, 7, 19b] Taken 
together, the data suggested that an enhanced uptake by the tumor tissues via the improved 
EPR effect was realized for GSH-Au25 NCs due to their ultrasmall HD and biocompatible 
surface. 
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The encouraging results from the in vitro radiation therapy and in vivo biodistribution studies 
on GSH- and BSA-Au25 NCs prompted an in vivo radiotherapy trial to further evaluate the 
potential of the new Au NC-based radiosensitizers for clinical use. Twenty-four male and 24 
female nude mice bearing the U14 tumor with a tumor weight of ~10 mg-tumor/kg-body were 
chosen as our animal model. The mice were intraperitoneally injected with GSH- or BSA-
Au25 NCs to a concentration of 10 mg-Au/kg-body. After 0.5 h, the mice were irradiated 
under 137Cs gamma radiation of 3600 Ci at a 5 Gy dose. After 20 days, the tumor volumes and 
weights in the sacrificed mice were measured (Figure 4a). As compared with the control 
group (p<0.05), remarkable decreases of ~55% and ~38% in tumor volume were observed in 
mice treated with GSH- and BSA-Au25 NCs, respectively. In addition, as compared with the 
mice treated by radiation only, the tumor volume decreased ~35% and ~10% in mice treated 
with GSH-Au25 NCs plus radiation (p<0.05) and BSA-Au25 NCs plus radiation (p<0.1), 
respectively. Figure 4b shows that the tumor weight decreased in mice treated with GSH- and 
BSA-Au25 NCs plus radiation. Similarly, as compared with the control group (p<0.05), 
significant tumor weight decreases of 55% and 39% were observed in mice treated with GSH- 
and BSA-Au25 NCs, respectively. The in vivo data further confirmed the strong radiation 
enhancement from the Au NCs for cancer radiotherapy. In addition, GSH-Au25 NCs showed 
better accumulation in tumors and therefore stronger enhancement for cancer radiotherapy 
than the BSA-Au25 NCs. 
 
The promising in vivo radiotherapy data of the GSH-Au25 NCs motivated us to study their in 
vivo cytotoxicity, which is pivotal to further developing this new class of radiosensitizer for 
clinical use. To achieve efficient cancer radiotherapy, the concentration of GSH-Au25 NCs 
was determined to be 10 mg-Au/kg-body. This concentration was similar to those used in 
other studies on therapeutic Au NPs [2b, 19a] and was therefore chosen as our model dose. No 
obvious abnormal organ index and loss of the body weight were observed in mice treated with 
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GSH-Au25 NCs (Figure S4). Figure 5a shows the pathological results for the heart, liver, 
spleen, lung, and kidney in mice treated with GSH-Au25 NCs, and there were no significant 
damages in these organs. In contrast, an obvious liver damage was observed in mice treated 
with BSA-Au25 NCs (Figure 5b and 5c). This damage could be related to the long-term 
accumulation of BSA-Au25 NCs in liver. Although a certain amount of the Au NCs (coated 
with GSH or BSA) were also accumulated in the genital system (e.g., testiculus), there were 
no obvious damages seen in these organs (Figure S5).  
 
To further understand the toxicological response that caused the liver damage in the BSA-
Au25 NC system, the hematology and blood biochemistry after 20 days of injection were 
analyzed (Figure 5b and 5c). The hepatic-related serum chemistry, which was highly related 
to the liver damage and liver function alternation, was the focus of our analysis. An obvious 
increase of aspartate aminotransferase (AST) and a distinctive decrease of red blood cell 
(RBC) were observed in mice treated with BSA-Au25 NCs (without radiation). There were no 
significant changes in other important indicators for liver injury, including alanine 
aminotransferase (ALT), albumin (ALB), and globulin (GLOB). Similar effects on the liver 
damage have recently been reported for the PEG-Au NP system, where the accumulation of 
PEG-Au NPs in liver could induce abnormal gene expression and lead to liver damage. The 
long retention time of BSA-Au25 NCs in liver could be attributed to its relatively large HD 
(~6 nm) because particles in this HD range (>5.5 nm) were difficult to be excreted through 
renal clearance.[13] In contrast, GSH-Au25 NCs had much smaller HD (~2.4 nm) and therefore 
had more efficient renal clearance. This was consistent with the observation that there was no 
visible toxicity in liver for the GSH-Au25 NC system. The low in vivo toxicity of GSH-Au25 
NCs further paves its way to potential clinical applications. Studies on the long-term toxicity 
and more rigorous toxicological evaluation are needed to further advance GSH-Au25 NCs as a 
new type of metabolizable and efficient clinical radiosensitizer for cancer radiotherapy. 
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3. Conclusion 
In summary, a new type of radiosensitizer was constructed by integrating ultrasmall Au NCs 
(<2 nm) with biocompatible coating ligands (GSH and BSA). The new nano-constructs 
(GSH- and BSA-Au25 NCs) inherit attractive features of both the Au core (strong 
radiotherapy enhancement from the Au atoms) and the coating shell (good biocompatibility 
conferred from the coating GSH or BSA). The ultrasmall Au25 NCs with biocompatible 
coating surface displayed higher tumor accumulation via the improved EPR effect and 
therefore had a stronger enhancement for cancer radiotherapy than that of much larger Au 
NPs. The enhanced radiotherapy was due to the DNA damage caused by the photoelectric 
effect and Compton scattering of the Au25 NCs. A remarkable decrease in tumor volume and 
weight was achieved by using the GSH-Au25 NCs as the radiosensitizer. In addition, the 
hydrodynamically ultrasmall GSH-Au25 NCs (HD ~2.4 nm) showed very efficient renal 
clearance and therefore had no obvious toxicity in the body, whereas the hydrodynamically 
larger BSA-Au25 NCs (HD ~6 nm) could not be efficiently removed by the kidney and 
therefore caused the liver damage. This work is of interest not only because it presents a new 
type of promising radiosensitizers that have preferential accumulation in tumors, strong 
radiotherapy enhancement, and can be metabolized after the treatment, but also because it 
exemplifies a good approach to improve the biocompatibility of functional nanomaterials by 
simply using a naturally occurring biomolecule (e.g., GSH) as the coating ligand. 
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4. Experimental Section  
Synthesis and Characterizations of GSH- and BSA-Au25 NCs: The synthesis and purification 
of GSH- and BSA-Au25 NCs followed published procedures.[14] In a typical synthesis of 
GSH-Au25 NCs, GSH in the reduced form (40 µmol) was mixed with a methanol solution of 
HAuCl4 (20 mL, 5 mM) at 4 °C for 30 min. An aqueous solution of NaBH4 (5 mL, 0.2 M, at 
0 °C) was then injected rapidly into the reaction mixture under vigorous stirring. The mixture 
was allowed to react at 4 °C for 1 h. The precipitate was collected and washed with methanol 
for three times. The precipitate was then dissolved in water (5 mL), and GSH (30 mg) was 
added to the solution. The solution was stirred and incubated at 55 °C for 3 h. UV-vis 
absorption spectroscopy was used to monitor the extent of reaction. In a typical synthesis of 
BSA-Au25 NCs, an aqueous solution of HAuCl4 (5 mL, 10 mM, 37 °C) was mixed with a 
BSA solution (5 mL, 50 mg/mL, 37 °C) under vigorous stirring. After two minutes, NaOH 
solution (0.5 mL, 1 M) was introduced, and the mixture was incubated at 37 °C for 12 h. Both 
GSH- and BSA-Au NCs were purified by using dialysis bags with a molecular weight cutoff 
(MWCO) of 3 kDa. The purified Au NCs were stored in fridge at 4 °C, and were ready for 
use. 
 
The hydrodynamic diameter (HD) distributions of the as-synthesized Au NCs were 
determined by dynamic light scattering (DLS) on a NanoZS Zetasizer (Malvern). The DLS 
data were acquired in the phase analysis light scattering mode at 25 °C, and the sample 
solutions were prepared by dissolving the Au NCs in 10 mM phosphate-buffered saline (PBS) 
solution (pH 7.0). The core sizes of the Au NCs were analyzed by transmission electron 
microscopy (TEM) on a JEM-2100F (JEOL) microscope operating at 200 kV. The UV-vis 
absorption spectra were recorded on a UV-1800 spectrophotometer (Shimadzu). The 
photoluminescence (PL) spectra were measured by a F4600 fluorescence spectrophotometer 
(Hitachi).  
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Fluorescent Labeling of GSH- and BSA-Au25 NCs: Cy5-SE (Fanbo Biochemicals Co., Ltd. 
Beijing, China) was used to label Au25 NCs according to a reported procedure.[18] In a typical 
modification, the as-synthesized Au25 NCs (1.5 mL, 1 mg-Au/mL) were mixed with Cy5-SE 
(1.5 mL, 0.1 mg/mL), and the mixture was allowed to react for 24 h in dark. The labeled Au25 
NCs were washed several times with copious water by ultrafiltration (2 kDa MWCO 
membranes) until no obvious blue color was observed in the filtrate. 
 
In vitro Cytotoxicity Test: Hela cells were cultured at 37 °C in humidified atmosphere with 
5% CO2 and low-glucose Dulbecco’s modified Eagle's medium (DMEM) which contained 
fetal calf serum (10%), L-glutamine (2.9 mg/mL), streptomycin (1 mg/mL) and penicillin 
(1000 units/mL). The cells (in culture medium) were dispensed in 96-well plates (90 µL 
containing 104 cells per well). Different concentrations of the Au25 NCs (10 μL) were then 
added to each well. The effect of the concentration of Au25 NCs was assessed using Cell 
Titre-Glo™ luminescent cell viability assay (Promega, Madison, WI, USA). After 24 or 48 h 
of treatment, 20 μL of Cell Titre-Glo™ reagent was added and mixed with the mixture in 
each well on an orbital shaker. The luminescence signal was recorded with a single tube 
luminometer (TD 20/20, Turner Biosystems Inc., Sunnyvale, CA, USA). The amount of ATP, 
which was proportional to the number of cells presented in culture, was determined from the 
assay. 
 
In vitro Radiation Therapy: Hela cells (1 × 103) were incubated in 25 cm2 flasks overnight 
and then exposed to the Au25 NCs (50 μg-Au/mL) for another 24 h. Cells were then irradiated 
under gamma-rays from 137Cs (photon energy 662 keV) with an activity of 3600 Ci at the 
doses of 1, 2, 4, 6, and 8 Gy. After irradiation, cells were trypsinized, counted, and seeded in 
6 cm dishes with a 5 mL culture medium. Six dishes were prepared for each dose. The cells 
ٛ ٛ 1 
   
were incubated for 10 days and then stained with crystal violet. The as-formed colonies were 
fixed and the surviving fraction was determined by the ratio of colony numbers in the 
irradiated cells to that in the untreated cells. Colonies with more than 50 cells were counted. 
The cell survival curve was fitted using a multi-target single-hit model ( NDDeS )1(1 0 ), 
where S is the surviving fraction and D is the radiation dose. The value of  was estimated 
from the fitting, and the sensitization enhancement ratio (SER) was determined by the 
radiation dose that led to a 50% survival of the cells.  
0D
 
In vitro DNA Break: A modified version of the alkaline COMET-assay protocol was 
performed to evaluate the DNA break. In a typical assay, frosted microscope slides were 
covered with 200 μL of 0.1% agarose in PBS. After the solidification of agarose, 2 × 105 cells 
suspended in 10 μL of PBS and 75 μL of 0.5% low-melting-point agarose were added to each 
slide. After solidification, the slides were placed in cold fresh lyses buffer [2.5 M NaCl, 100 
mM disodium ethylenediaminetetraacetate (EDTA), 10 mM Tris-HCl, and 1% Triton X-100] 
for 1 h and subsequently in a horizontal gel electrophoresis unit (20 × 25 cm) filled with 
chilled electrophoresis buffer (300 mM NaOH and 1 mM Na2EDTA) for 30 min. 
Electrophoresis was then conducted at 14 V for 1 h. The slides were drained, neutralized, and 
dried with ethanol after the electrophoresis. The comets were stained with ethidium bromide. 
The DNA damage was analyzed using Comet Assay Software Project (CASP) software that 
measures the tail moment. 
 
In vivo Imaging: All animals were purchased, maintained, and handled using protocols 
approved by the Institute of Radiation Medicine, Chinese Academy of Medical Sciences 
(CAMS). The U14 tumor models were generated by subcutaneous injection of 2 × 106 cells 
suspended in 50 μL of PBS into the right shoulder of male nude mice. Before the experiments, 
the mice were anesthetized by chloral hydrate. The Cy5-labeled GSH-Au NCs (150 μL, 1 mg-
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Au/mL) and BSA-Au NCs (150 μL, 1 mg-Au/mL) were respectively intraperitoneally 
injected into two groups of male nude mice (three mice per group) at day 7 after the tumor 
inoculation when the tumor volume reached 100–120 mm3. The Au NCs were then imaged 
using the in vivo fluorescence imaging system (Caliper Inc.). Visible red light with a central 
wavelength of 595 nm was used as the excitation source. The in vivo imaging wavelength 
range was 610–800 nm with an exposure time of 82 and 76 ms. Autofluorescence was 
removed using the spectral unmixing software. In the biodistribution and blood concentration 
measurement, the organ tissues were homogenized in the buffered formalin, and the resultant 
tissue suspensions were diluted 100 times. The photoluminescence intensity of the samples 
was measured at the excitation wavelength of 595 nm. The photoluminescence intensities of 
both standard samples and tissue samples were all adjusted to a linear range. The 
biodistribution of the Au NCs in the organs of the mice was obtained and plotted with the unit 
of % ID/g (percentage of the injected dose per gram-tissue). 
 
In vivo Radiation Therapy: All animals were purchased, maintained, and handled using 
protocols approved by the Institute of Radiation Medicine, CAMS. The U14 tumor models 
were generated by subcutaneous injection of 2 × 106 cells suspended in 50 μL of PBS into the 
right shoulder of BALB/c mice. The mice were intraperitoneally treated with the GSH- and 
BSA-Au25 NCs when the tumor volume reached 100–120 mm3 (7 days after tumor 
inoculation). For each treatment, Au25 NCs (1 mg-Au/mL) were intraperitoneally injected at a 
dosage of 10 mg/kg in the mice. As the control, 200 μL of saline was intraperitoneally 
injected into each mouse in the control group. Subsequently, the mice were irradiated by 5 Gy 
gamma-rays from 137Cs (photon energy 662 keV) with an activity of 3600 Ci. 48 mice were 
assigned to the following six groups (eight mice per group): control, GSH-Au25 NCs, BSA-
Au25 NCs, radiation alone, GSH-Au25 NCs + radiation, BSA-Au25 NCs + radiation. Every 
group includes four male and four female mice in order to monitor the gender difference. The 
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tumor size was measured every two or three days and calculated using the equation: tumor 
volume = (tumor length) × (tumor width)2 / 2. 
 
In vivo Toxicity: Mice were weighed and assessed for behavioral changes. At day 20 after the 
treatment, all mice were sacrificed, and their blood and organs were collected for hematology, 
biochemistry and toxicological investigation. The blood was drawn for hematology analysis 
(potassium EDTA collection tube) and serum biochemistry analysis (lithiumheparin collection 
tube) using a standard saphenous vein blood collection technique. During necropsy, liver, 
kidney, spleen, heart, lung, brain, genitals, tumor, and thyroid were collected and weighed. 
The spleen and thymus indexes (Sx) were used to examine the grade of changes caused by 
malities. The definition of Sx is shown as below: 
 
)( animalalexperimentofWeight
)(organ alexperimentofWeight
S
g
mg
x   
Major organs from these mice were then fixed in 4% neutral buffered formalin, processed into 
paraffin, and stained with hematoxylin and eosin (H&E). Pathology was examined using a 
digital light microscope. The organs and original solutions of BSA- and GSH-Au25 NCs were 
digested using a microwave system CEM Mars 5 (CEM, Kamp Lintfort, Germany) to 
determine their Au content, which was measured on an inductively coupled plasma mass 
spectrometer (Agilent 7500 CE, Agilent Technologies, Waldbronn, Germany).  
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Figure 1. Schematic illustration of the core-shell structure of (a) GSH-Au25 NCs and (b) 
BSA-Au25 NCs. (c) UV-vis and (d) DLS spectra of the as-prepared GSH-Au25 NCs (black 
line) and BSA-Au25 NCs (red line). Representative TEM images of the as-prepared (e) GSH-
Au25 NCs and (f) BSA-Au25 NCs.  
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Figure 2. (a) Viability of Hela cells after incubation with GSH- and BSA-Au25 NCs for 24 
and 48 h. (b) Viability of Hela cells treated with only radiation (control, black line), GSH-
Au25 NCs (50 μg-Au/mL) + radiation (red line), and BSA-Au25 NCs (50 μg-Au/mL) + 
radiation (blue line). (c) Tail moment of Hela cells treated with GSH-Au25 NCs, BSA-Au25 
NCs, radiation (3 Gy), GSH-Au25 NCs + radiation (3 Gy), and BSA-Au25 NCs + radiation (3 
Gy). Representative cell images of fluorescent DNA stain of (d) radiation group, (e) GSH-
Au25 NCs + radiation (3 Gy), and (f) BSA-Au25 NCs + radiation (3 Gy). 
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Figure 3. (a) In vivo pharmacokinetic studies of GSH-Au25 NCs (black line) and BSA-Au25 
NCs (red line). (b) Fluorescence images of mice treated with GSH-Au25 NCs (left panel) and 
BSA-Au25 NCs (middle panel) at 2 h after injection; the right panel is the tumor images (false 
color) at 24 h after injection of the control group (top), GSH-Au25 NCs group (middle), and 
BSA-Au25 NCs group (down). (c) Biodistribution of GSH-Au25 NCs (black column) and 
BSA-Au25 NCs (red column) at 24 h after injection. 
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Figure 4. Time-course studies of tumor (a) volumes and (b) weights of mice treated with 
GSH- and BSA-Au25 NCs at the concentration of 10 mg-Au/kg-body. Data was analyzed by 
Student’s t-test and * in (b) indicates p < 0.05. 
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Figure 5. (a) Pathological data from the liver, spleen, kidney, lung, and heart of mice treated 
with GSH- and BSA-Au25 NCs at the concentration of 10 mg-Au/kg-body. (b) Hematology 
data of mice treated with GSH- and BSA-Au25 NCs at day 20 after injection. The results show 
mean and standard deviation of white blood cells (WBC), RBC, hematocrit (HCT), mean 
corpuscular volume (MCV), hemoglobin (HGB), platelets (PLT), mean corpuscular 
hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC). (c) Blood 
biochemistry analysis of mice treated with GSH- and BSA-Au25 NCs at day 20 after injection. 
The results show mean and standard deviation of ALT, AST, total protein (TP), ALB, blood 
urea nitrogen (BUN), creatinine (CREA), GOLB, and total bilirubin (TB). Data was analyzed 
by Student’s t-test and * in (b) and (c) indicates p < 0.05. 
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Figure S1. Representative images of fluorescent DNA stain of (a) untreated cells (control 
group) and cells treated by (b) GSH-Au25 NCs and (c) BSA-Au25 NCs (50 μg-Au/mL). 
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Figure S2. Photoemission spectra of Au25 NCs with and without Cy5 labeling. 
 
 
 
Figure S3. The biodistribution (in terms of Au content, determined by ICP-MS) of GSH- and 
BSA-Au25 NCs at day 20 after the injection of the NCs.  
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Figure S4. Body and organ index of the GSH- and BSA-Au25 NCs. 
 
 
 
Figure S5. Pathological image of the thymus and testiculus from the untreated mice (control 
group) and the mice treated with GSH- and BSA-Au25 NCs. 
 
